Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The eye presents extensive perspectives and challenges for drug delivery, mainly because of the extraordinary capacity, intrinsic to this path, for drugs to permeate into the main circulatory system and also for the restrictions of the ocular barriers. Depending on the target segment of the eye, anterior or posterior, the specifications are different. The ocular route experienced in the last decades a lot of progresses related with the development of new drugs, improved formulations, specific-designed delivery and even new routes to administer a drug. Concomitantly, new categories of materials were developed and adapted to encapsulate drugs. With such advances, a multiplicity of parameters became possible to be optimized as the increase in bioavailability and decreased toxic effects of medicines. Also, the formulations were capable to easily adhere to specific tissues, increase the duration of the therapeutic effect and even target the delivery of the treatment. The ascending of new delivery systems for ocular targeting is a current focus, mainly because of the capacity to extend the normal time during which the drug exerts its therapeutic effect and, so, supplying the patients with a product which gives them fewer side effects, fewer number of applications and even more effective outcomes to their pathologies, surpassing the traditionally-used eye drops. Depending on the systems, some are capable of increasing the duration of the drug action as gels, emulsions, prodrugs, liposomes, and ocular inserts with hydrophilic properties, improving the absorption by the cornea. In parallel, other devices use as a strategy the capacity to sustain the release of the carried drugs by means of erodible and non-erodible matrices. This review discusses the different types of advanced formulations used for ocular delivery of therapeutics presenting the most recent patents according to the clinical applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insoluble drug delivery strategies: review of recent advances and business prospects
Kalepu, S., & Nekkanti, V. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.07.003 · Cited by 1,410
Gaudana, R., Ananthula, H. K., Parenky, A., & Mitra, A. K. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9183-3 · Cited by 1,406 · cited 2×
“Yet, to achieve an effective ocular distribution of the drug using eye-drops it is mandatory to achieve a higher retention time in the corneal tissue and elevated corneal permeation [3,10].”
BackgroundSafety evaluation of ocular drug delivery formulations: Techniques and practical considerations
Short, B. G. (2008) · Toxicologic Pathology · doi:10.1177/0192623307310955 · Cited by 244
Advances in ophthalmic drug delivery
Morrison, P. W., & Khutoryanskiy, V. V. (2014) · Therapeutic Delivery · doi:10.4155/tde.14.75 · Cited by 196
Technique of retinal gene therapy: delivery of viral vector into the subretinal space
Xue, K., Groppe, M., Salvetti, A. P., & MacLaren, R. E. (2017) · Eye · doi:10.1038/eye.2017.158 · Cited by 191 · cited 1×
“Although the experiences in animal models have been a success, a much more careful planning and regulation of these complex, dangerous, but, in parallel, extremely advantageous systems is required, to be applied in human trials to further assess possible extrapolations targeting future therapeutics for until now uncur…”
BackgroundPolyhydroxyethylaspartamide-based micelles for ocular drug delivery
Civiale, C., Licciardi, M., Cavallaro, G., Giammona, G., & Mazzone, M. G. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.05.028 · Cited by 120 · cited 1×
“The results pointed to the worthwhile opportunity of applying these formulations of nanomicelles to deliver small molecules to the ocular tissue by topical application [154].”
BackgroundTopical, aqueous, clear cyclosporine formulation design for anterior and posterior ocular delivery
Cholkar, K., Gilger, B. C., & Mitra, A. K. (2015) · Translational Vision Science & Technology · doi:10.1167/tvst.4.3.1 · Cited by 103
Advances in gene therapy for diseases of the eye
Petit, L., Khanna, H., & Punzo, C. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.040 · Cited by 82
Drug delivery to the posterior segment of the eye
Moisseiev, E., & Loewenstein, A. (2017) · Developments in Ophthalmology · doi:10.1159/000455276 · Cited by 46
Cited by
Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects
Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., & Alcudia, A. (2020) · Nanomaterials · doi:10.3390/nano10071403 · Cited by 1,061
Lohia, A., Sahel, D. K., Salman, M., Singh, V., Mariappan, I., Mittal, A., & Chitkara, D. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.02.001 · Cited by 33
Metadata
- Authors
- Souto, E. B., Dias-Ferreira, J., López-Machado, A., Ettcheto, M., Cano, A., Camins Espuny, A., Espina, M., Garcia, M. L., & Sánchez-López, E.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2019-09-06
- Volume
- 11
- Issue
- 9
- Pages
- 460
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W2971876988
- Cited by
- 193
- References
- 9
- FWCI
- 7.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.